{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:28:08Z","timestamp":1792794488221,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02070-1","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T09:46:33Z","timestamp":1772703993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7851-6313","authenticated-orcid":false,"given":"Fatemeh","family":"Shakibaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6521-946X","authenticated-orcid":false,"given":"Sepehr","family":"Malekshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-4926","authenticated-orcid":false,"given":"Nazila","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-8814","authenticated-orcid":false,"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"9","key":"2070_CR1","doi-asserted-by":"publisher","first-page":"e0290289","DOI":"10.1371\/journal.pone.0290289","volume":"18","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wang Z, Zhang D, Ye D, Zhou Y, Qin J, et al. The prevalence and treatment rate trends of osteoporosis in postmenopausal women. PLoS One. 2023;18(9):e0290289.","journal-title":"PLoS One"},{"issue":"1","key":"2070_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.69","volume":"2","author":"R Eastell","year":"2016","unstructured":"Eastell R, O\u2019Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2(1):16069.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2070_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.eprac.2021.02.001","volume":"27","author":"NB Watts","year":"2021","unstructured":"Watts NB, Camacho PM, Lewiecki EM, Petak SM, Force AAPOGT. American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract. 2021;27(4):379\u201380.","journal-title":"Endocr Pract"},{"issue":"9","key":"2070_CR4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/GME.0000000000001831","volume":"28","author":"Management of osteoporosis in","year":"2021","unstructured":"Management of osteoporosis in. Postmenopausal women: the 2021 position statement of the North American menopause society. Menopause. 2021;28(9):973\u201397.","journal-title":"Menopause"},{"key":"2070_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.maturitas.2021.10.010","volume":"156","author":"KN Ruiz-Esteves","year":"2022","unstructured":"Ruiz-Esteves KN, Teysir J, Schatoff D, Yu EW, Burnett-Bowie SM. Disparities in osteoporosis care among postmenopausal women in the United States. Maturitas. 2022;156:25\u20139.","journal-title":"Maturitas"},{"key":"2070_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/978-981-13-3681-2_16","volume":"91","author":"TJ Aspray","year":"2019","unstructured":"Aspray TJ, Hill TR. Osteoporosis and the ageing skeleton. Subcell Biochem. 2019;91:453\u201376.","journal-title":"Subcell Biochem"},{"issue":"1","key":"2070_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-022-00219-8","volume":"10","author":"S Bolamperti","year":"2022","unstructured":"Bolamperti S, Villa I, Rubinacci A. Bone remodeling: an operational process ensuring survival and bone mechanical competence. Bone Res. 2022;10(1):48.","journal-title":"Bone Res"},{"issue":"1","key":"2070_CR8","first-page":"9","volume":"1","author":"MX Ji","year":"2015","unstructured":"Ji MX, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med. 2015;1(1):9\u201313.","journal-title":"Chronic Dis Transl Med"},{"issue":"7","key":"2070_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041605","volume":"104","author":"A Akbar","year":"2025","unstructured":"Akbar A, Zaheer A, Kharal MM, Komel A, Khan MH, Ahsan A, et al. Evolving strategies for osteoporosis management in postmenopausal women: from tradition to innovation. Medicine (Baltimore). 2025;104(7):e41605.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2070_CR10","first-page":"92","volume":"43","author":"KN Tu","year":"2018","unstructured":"Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: a review of treatment options. P t. 2018;43(2):92\u2013104.","journal-title":"P t"},{"issue":"1","key":"2070_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-022-00371-3","volume":"27","author":"B Liang","year":"2022","unstructured":"Liang B, Burley G, Lin S, Shi YC. Osteoporosis pathogenesis and treatment: existing and emerging avenues. Cell Mol Biol Lett. 2022;27(1):72.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"2070_CR12","doi-asserted-by":"publisher","DOI":"10.1515\/biol-2022-0759","volume":"18","author":"Z Na","year":"2023","unstructured":"Na Z, Wei W, Xu Y, Li D, Yin B, Gu W. Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis. Open Life Sci. 2023;18(1):20220759.","journal-title":"Open Life Sci"},{"key":"2070_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/B978-0-12-817134-9.00006-4","volume-title":"Overcoming Obstacles in drug discovery","author":"G Jang","year":"2023","unstructured":"Jang G. Denosumab: dosing and drug interaction challenges on the path to approval. In: He K, Hollenberg PF, Wienkers LC, editors. Overcoming Obstacles in drug discovery. and Development: Academic; 2023. pp. 63\u201374."},{"issue":"8","key":"2070_CR14","first-page":"469","volume":"6","author":"EA Blackstone","year":"2013","unstructured":"Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469\u201378.","journal-title":"Am Health Drug Benefits"},{"issue":"8","key":"2070_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14712598.2025.2540471","volume":"25","author":"M Aapro","year":"2025","unstructured":"Aapro M, Hadji P, Santini D, Schmidmaier R, Eastell R. Biosimilars in osteoporosis treatment: focus on denosumab. Expert Opin Biol Ther. 2025;25(8):887\u201398.","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"2070_CR16","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00198-024-07161-x","volume":"35","author":"JY Reginster","year":"2024","unstructured":"Reginster JY, Czerwinski E, Wilk K, Borowy P, Strzelecka A, Budlewski T, et al. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, phase 3 trial in postmenopausal women with osteoporosis. Osteoporos Int. 2024;35(11):1919\u201330.","journal-title":"Osteoporos Int"},{"issue":"2","key":"2070_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41401-022-00954-y","volume":"44","author":"H Zhang","year":"2023","unstructured":"Zhang H, Gu JM, Chao AJ, Cheng Q, Teng DH, Yu JM, et al. A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk. Acta Pharmacol Sin. 2023;44(2):446\u201353.","journal-title":"Acta Pharmacol Sin"},{"key":"2070_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The prisma 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"1","key":"2070_CR19","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.59556\/japi.73.0772","volume":"73","author":"T Paul","year":"2025","unstructured":"Paul T, Garg B, Kapoor N, Patil V, Kachnerkar N, Shembalkar J, et al. A prospective, active-controlled, randomized, double-blind, multicenter, phase III study to compare the safety and efficacy of biosimilar denosumab vs reference denosumab in the treatment of postmenopausal osteoporosis. J Assoc Physicians India. 2025;73(1):e8\u201313.","journal-title":"J Assoc Physicians India"},{"key":"2070_CR20","doi-asserted-by":"publisher","first-page":"117371","DOI":"10.1016\/j.bone.2024.117371","volume":"192","author":"YS Chung","year":"2025","unstructured":"Chung YS, Langdahl B, Plebanski R, Czerwinski E, Dokoupilova E, Supronik J, et al. SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial. Bone. 2025;192:117371.","journal-title":"Bone"},{"key":"2070_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16","author":"J Sadek","year":"2024","unstructured":"Sadek J, Valter I, de Souza A, Szeles P, Monnet J. A randomized, double-blind, study to evaluate the efficacy, pharmacodynamics, safety and immunogenicity of FKS518 proposed biosimilar to denosumab with the originator in postmenopausal women with osteoporosis (LUMIADE-3 study). J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/jco.2024.42.16.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2070_CR22","doi-asserted-by":"publisher","first-page":"e1951","DOI":"10.1210\/clinem\/dgae611","volume":"110","author":"B Langdahl","year":"2025","unstructured":"Langdahl B, Chung YS, Plebanski R, Czerwinski E, Dokoupilova E, Supronik J, et al. Proposed denosumab biosimilar SB16 vs reference denosumab in postmenopausal osteoporosis: phase 3 results up to month 12. J Clin Endocrinol Metab. 2025;110(6):e1951\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2070_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/jbmr\/zjae016","volume":"39","author":"S Jeka","year":"2024","unstructured":"Jeka S, Dokoupilova E, Kivitz A, Zuchowski P, Vogg B, Krivtsova N, et al. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. J Bone Min Res. 2024;39(3):202\u201310.","journal-title":"J Bone Min Res"},{"issue":"1","key":"2070_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02840-8","volume":"24","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi A, Vojdanian M, Soroush M, Akbarian M, Aghaei M, Hajiabbasi A, et al. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia(R)) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial. Arthritis Res Ther. 2022;24(1):161.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2070_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/ijp.IJP_346_19","volume":"53","author":"I Singh","year":"2021","unstructured":"Singh I, Jose V, Patel R, Arora S. Denosumab biosimilar in postmenopausal osteoporotic women: a randomized, assessor-blind, active-controlled clinical trial. Indian J Pharmacol. 2021;53(1):6\u201312.","journal-title":"Indian J Pharmacol"},{"issue":"7","key":"2070_CR26","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/14712598.2024.2352587","volume":"24","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Huo Y, Li Y, Kong X, Wang B, Liu F, et al. Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis. Expert Opin Biol Ther. 2024;24(7):665\u201372.","journal-title":"Expert Opin Biol Ther"},{"key":"2070_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jot.2022.06.007","volume":"38","author":"J Gu","year":"2023","unstructured":"Gu J, Zhang H, Xue Q, Wang L, Cheng Z, Zhang Y, et al. Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: a randomized, double-blind, placebo-controlled, multicenter phase III study. J Orthop Translat. 2023;38:117\u201325.","journal-title":"J Orthop Translat"},{"key":"2070_CR28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae611","author":"B Langdahl","year":"2024","unstructured":"Langdahl B, Chung YS, Plebanski R, Czerwinski E, Dokoupilova E, Supronik J, et al. Proposed denosumab biosimilar SB16 vs reference denosumab in postmenopausal osteoporosis: phase 3 results up to month 12. J Clin Endocrinol Metab. 2025 May 19;110(6):e1951-e1958. https:\/\/doi.org\/10.1210\/clinem\/dgae611.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2070_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02840-8","volume":"24","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi A, Vojdanian M, Soroush M, Akbarian M, Aghaei M, Hajiabbasi A, et al. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia\u00ae) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial. Arthritis Res Ther. 2022;24(1):161.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2070_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13619-024-00205-x","volume":"13","author":"Q Xiang","year":"2024","unstructured":"Xiang Q, Li L, Ji W, Gawlitta D, Walboomers XF, van den Beucken JJJP. Beyond resorption: osteoclasts as drivers of bone formation. Cell Regen. 2024;13(1):22.","journal-title":"Cell Regen"},{"issue":"4","key":"2070_CR31","volume":"4","author":"D Patel","year":"2025","unstructured":"Patel D, Saxena B. Decoding osteoporosis: understanding the disease, exploring current and new therapies and emerging targets. J Orthop Rep. 2025;4(4):100472.","journal-title":"J Orthop Rep"},{"issue":"4","key":"2070_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00418-018-1636-2","volume":"149","author":"T Ono","year":"2018","unstructured":"Ono T, Nakashima T. Recent advances in osteoclast biology. Histochem Cell Biol. 2018;149(4):325\u201341.","journal-title":"Histochem Cell Biol"},{"issue":"2","key":"2070_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40266-018-0525-7","volume":"35","author":"ED Deeks","year":"2018","unstructured":"Deeks ED. Denosumab: a review in postmenopausal osteoporosis. Drugs Aging. 2018;35(2):163\u201373.","journal-title":"Drugs Aging"},{"issue":"7","key":"2070_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513\u201323.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2070_CR35","unstructured":"Administration UFaD. Prolia\u00ae (denosumab): US prescribing information. [Available from: https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Prolia\/prolia_pi.pdf"},{"issue":"2","key":"2070_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/2229-516X.136774","volume":"4","author":"R Kumar","year":"2014","unstructured":"Kumar R, Singh J. Biosimilar drugs: current status. Int J Appl Basic Med Res. 2014;4(2):63\u20136.","journal-title":"Int J Appl Basic Med Res"},{"issue":"10","key":"2070_CR37","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.drudis.2019.06.016","volume":"24","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, Schellekens H. Are we ready to close the discussion on the interchangeability of biosimilars? Drug Discov Today. 2019;24(10):1963\u20137.","journal-title":"Drug Discov Today"},{"key":"2070_CR38","doi-asserted-by":"publisher","DOI":"10.2174\/0118743129363221241226103554","author":"S Bandyopadhyay","year":"2025","unstructured":"Bandyopadhyay S, Dastidar AG, Chandra S, Dutta A, Samanta R, Singhal P, et al. Biosimilar denosumab in osteoporotic patients attending a tertiary care hospital of Eastern India: a real-world comparative retrospective observational study. Open Rheumatol J. 2025;19: e18743129363221. https:\/\/doi.org\/10.2174\/0118743129363221241226103554.","journal-title":"Open Rheumatol J"},{"key":"2070_CR39","doi-asserted-by":"publisher","unstructured":"Lee YH, Song GG. Comparative efficacy and safety of denosumab biosimilar and originator in postmenopausal osteoporosis: a meta-analysis of randomized controlled trials. Z Rheumatol. 2025. Sep 24. English. 1.0 Q4. Epubahead of print.https:\/\/doi.org\/10.1007\/s00393-025-01737-6IF","DOI":"10.1007\/s00393-025-01737-6IF"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02070-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02070-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02070-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:02:03Z","timestamp":1773248523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02070-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2070"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02070-1","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"176"}}